Senate Hearing on the Opioid Crisis: State and Local Perspectives
January 1, 2022
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
The Frame
This hearing serves as a formal record of testimony from state-level experts and providers, which informs potential future federal legislation regarding opioid prescribing practices and addiction response strategies.
Potentially affected actors named in the source documents. Mention is not a position.
Healthcare providers
Providers are subject to evolving prescribing guidelines and educational requirements regarding opioid management.
State health departments
State agencies are responsible for implementing prescription drug monitoring programs and managing local addiction response services.
Last recorded activity January 1, 2022.
Next step not available in the current record.
Summary
Key Facts
- The hearing took place on November 30, 2017, in the Dirksen Senate Office Building.
- This was the second in a series of bipartisan hearings held by the committee regarding the opioid crisis.
- Dr. A. Omar Abubaker testified regarding his personal experience with his son's opioid addiction and overdose.
- The hearing included testimony from state officials representing Rhode Island, Wisconsin, and Kentucky.
- The committee examined the role of prescription drug monitoring programs and the perspectives of healthcare providers.
- The hearing was held concurrently with a Senate tax debate, affecting member attendance.
Frequently Asked Questions
What was the purpose of this hearing?
Who testified at the hearing?
Why It Matters
This hearing serves as a formal record of testimony from state-level experts and providers, which informs potential future federal legislation regarding opioid prescribing practices and addiction response strategies.
News Coverage
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Focus on State-Level Data
The hearing highlights a shift toward utilizing state-level prescription monitoring data to inform federal policy responses.
Connected Entities
Sources
www.govinfo.gov
Analysis Score
0–100- Significance65How much this matters to a regular citizen
- Controversy10Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz15Current news / social attention level
Publisher tools